Long-Term Safety Study of Lisocabtagene Maraleucel Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in a Post-Marketing Setting

What this Trial Is About

Researchers are studying the long-term safety of lisocabtagene maraleucel liso-cel in patients who have relapsed or refractory chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. This study is part of post-marketing pharmacovigilance activities to monitor patients treated with liso-cel outside of clinical trials. The study observes patients who have received at least one infusion of lisocabtagene maraleucel according to the approved U.S. prescribing information and commercial product specifications. It is a non-interventional observational study monitoring these patients in their regular care setting without assigning specific treatments. Participants will be followed for up to 15 years to record adverse events and evaluate outcomes such as complete remission rate, overall response rate, progression-free survival, and overall survival. Data collection will focus on safety and effectiveness measures to better understand the long-term impact of liso-cel treatment.

A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting